ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

מאת Sullivan, Ivana, Planchard, David
הוצא לאור ב Ther Adv Med Oncol (2016)

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

מאת Sullivan, Ivana, Planchard, David
הוצא לאור ב J Thorac Dis (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

מאת Sullivan, Ivana, Planchard, David
הוצא לאור ב Front Med (Lausanne) (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

מאת Mezquita, Laura, Planchard, David
הוצא לאור ב Cancer Manag Res (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

מאת Sullivan, Ivana, Planchard, David
הוצא לאור ב Ther Adv Respir Dis (2016)

Oncogene addiction and immune escape: friends or foes?

מאת Abdayem, Pamela, Planchard, David
הוצא לאור ב Ann Transl Med (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

מאת Abdayem, Pamela, Planchard, David
הוצא לאור ב Transl Lung Cancer Res (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

מאת Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
הוצא לאור ב Ther Adv Respir Dis (2019)

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

מאת Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
הוצא לאור ב Front Oncol (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

מאת Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
הוצא לאור ב Cancer Manag Res (2021)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

מאת Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric
הוצא לאור ב PLoS One (2018)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

מאת Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
הוצא לאור ב J Cachexia Sarcopenia Muscle (2019)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

מאת Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange
הוצא לאור ב ESMO Open (2020)

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

מאת Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline
הוצא לאור ב JAMA Oncol (2020)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

מאת Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
הוצא לאור ב Oncotarget (2017)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

מאת Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
הוצא לאור ב NPJ Precis Oncol (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

מאת Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
הוצא לאור ב Invest New Drugs (2020)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

מאת Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
הוצא לאור ב Br J Cancer (2019)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

מאת Remon, Jordi, Swalduz, Aurelie, Planchard, David, Ortiz-Cuaran, Sandra, Mezquita, Laura, Lacroix, Ludovic, Jovelet, Cecile, Rouleau, Etienne, Leonce, Camille, De Kievit, Frank, Morris, Clive, Jones, Greg, Mercier, Kelly, Howarth, Karen, Green, Emma, Pérol, Maurice, Saintigny, Pierre, Besse, Benjamin
הוצא לאור ב PLoS One (2020)

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

מאת Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
הוצא לאור ב Lancet Oncol (2016)